<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970134</url>
  </required_header>
  <id_info>
    <org_study_id>TTCC-2020-02</org_study_id>
    <nct_id>NCT04970134</nct_id>
  </id_info>
  <brief_title>Spanish Study for Molecular Characterization of Thyroid Carcinoma</brief_title>
  <acronym>MOLTHY</acronym>
  <official_title>Spanish Observational Study for MOLecular Characterization of THYroid Carcinoma MOLTHY Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Tratamiento de Tumores de Cabeza y Cuello</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Español de Tratamiento de Tumores de Cabeza y Cuello</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is a retrospective observational study based on the molecular characterization&#xD;
      of a Spanish population of patients with refractory radio-iodine differentiated thyroid&#xD;
      cancer (DTC) and medullary thyroid carcinoma (MTC) with advanced and / or metastatic disease&#xD;
      undergoing systemic treatment, or under clinical observation.&#xD;
&#xD;
      Three diagnostic techniques will be performed on formalin-fixed paraffin embedded (FFPE)&#xD;
      tumor samples from the study population: immunohistochemistry (IHC), fluorescence by in situ&#xD;
      hybridization (FISH) as well as Next-Generation Sequencing (NGS) techniques by means of DNA&#xD;
      and RNA analysis (Ion Platform Torrent - Oncomine Focus Assay, 52 gene detection). The&#xD;
      results of each patient will be compared in order to correlate the results of each method.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques will be&#xD;
      carried out to identify NTRK and RET alterations. NTRK alterations will be identified using&#xD;
      IHC techniques (NTRK over-expression), and FISH techniques (break-apart method). RET&#xD;
      alterations will also be identified using the FISH technique (break-apart method).&#xD;
&#xD;
      At the same time, DNA and RNA will be extracted for sequencing techniques using the Oncomine&#xD;
      Focus Assay platform, including 52 genes (35 Hotspot genes, 19 Copy number variants and 23&#xD;
      Gene fusions, including NTRK and RET).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Throughout the study. Approximately 2 years</time_frame>
    <description>Time from start of data capture (retrospectively) to progression disease. Patients may be stratified in subgroups attending to their histologic subtype and molecular genetic profile.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Throughout the study. Approximately 2 years</time_frame>
    <description>Time from start of data capture (retrospectively) to death. Patients may be stratified in subgroups attending to their histologic subtype and molecular genetic profile.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Throughout the study. Approximately 2 years</time_frame>
    <description>Response to systemic treatments received if available. Patients may be stratified in subgroups attending to their histologic subtype and molecular genetic profile.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of genetic alterations</measure>
    <time_frame>Throughout the study. Approximately 2 years</time_frame>
    <description>Frequency of genetic alterations in the study population determined by the molecular genetic interventions: IHC, FISH and NGS</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Differentiated Thyroid Carcinoma</condition>
  <condition>Medullary Thyroid Carcinoma</condition>
  <arm_group>
    <arm_group_label>Thyroid carcinoma</arm_group_label>
    <description>Advanced and / or metastatic thyroid carcinoma with initial histological diagnosis date before January 1, 2021 of the types:&#xD;
Differentiated thyroid carcinoma (DTC) refractory to radio-iodine, including papillary carcinomas, follicular carcinomas, poorly differentiated carcinomas of the thyroid and the different corresponding variants.&#xD;
Medullary thyroid carcinoma (MTC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immunohistochemistry (IHC)</intervention_name>
    <description>VENTANA pan-TRK technique (EPR17341) Assay, with Optiview DAB-detection kit and Optiview amplification kit. Using FFPE slices</description>
    <arm_group_label>Thyroid carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluorescence In-Situ Hybridization (FISH)</intervention_name>
    <description>FISH using FFPE slices for genes: Neurotrophic tyrosin kinase 1 (NTRK1), Neurotrophic tyrosin kinase 3 (NTRK3) and rearranged during transfection (RET)</description>
    <arm_group_label>Thyroid carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oncomine Focus Assay Platform with 52 genes</intervention_name>
    <description>Oncomine Focus Assay Platform with 52 genes (35 Hotspot genes, 19 Copy number variants and 23 Gene fusions). Using FFPE slices</description>
    <arm_group_label>Thyroid carcinoma</arm_group_label>
    <other_name>Next Generation Sequencing (NGS)</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tumor sample from each patient in formalin-fixed paraffin block (FFPE)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        It is estimated to include 150 patients over 18 years of age with thyroid carcinoma&#xD;
        (radioiodine resistant differentiated thyroid carcinoma and medullary thyroid carcinoma)&#xD;
        undergoing systemic treatment or under clinical follow-up.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. All participants must be over 18 years old&#xD;
&#xD;
          2. Obtaining the informed consent signed by the patient or his legal representative.&#xD;
&#xD;
          3. Have a paraffinized tumor sample available for analysis in the central laboratory,&#xD;
             preferably from total thyroidectomy.&#xD;
&#xD;
          4. Life expectancy greater than 6 months.&#xD;
&#xD;
          5. Thyroid carcinoma with a date of initial histological diagnosis before January 1, 2021&#xD;
             of the types:&#xD;
&#xD;
        (1) Differentiated thyroid carcinoma (DTC) refractory to radio-iodine, including papillary&#xD;
        carcinomas, follicular carcinomas, poorly differentiated thyroid carcinomas, and the&#xD;
        corresponding different variants. The radio-refractoriness criteria will be defined by&#xD;
        medical criteria and / or by decision of the tumor committee (depending on the organization&#xD;
        of each hospital) or (2) Medullary thyroid carcinoma (MTC). 6. Potential candidate patients&#xD;
        must meet at least one of the following premises:&#xD;
&#xD;
          1. Patients with advanced / metastatic disease in wait &amp; see follow-up.&#xD;
&#xD;
          2. Patients with advanced / metastatic disease currently undergoing treatment or in&#xD;
             progression to any type of multikinase inhibitor, such as, for example: sorafenib,&#xD;
             lenvatinib, cabozantinib, axitinib, vandetanib, ...&#xD;
&#xD;
          3. Patients with advanced / metastatic disease under treatment or in progression to&#xD;
             treatments that inhibit immune checkpoints (anti programed death (PD-1) or its ligand&#xD;
             (PD-L1), anti Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), others) or who are&#xD;
             participating in clinical trial regimen. They must be patients who have previously&#xD;
             progressed to multikinase inhibitors.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients affected by other malignant histologies not mentioned in the previous section&#xD;
             (eg melanoma, lymphoma, sarcoma, ...) or benign tumors exclusively of the thyroid&#xD;
             gland.&#xD;
&#xD;
          2. Patients with radioiodine sensitive differentiated thyroid carcinoma or anaplastic&#xD;
             thyroid carcinomas.&#xD;
&#xD;
          3. Patients with refractory radioiodine differentiated thyroid carcinoma and advanced&#xD;
             medullary thyroid carcinomas with the possibility of local ablative treatment with&#xD;
             radical or curative intent (surgery, radiosurgery, radio-ablation, ...).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neus Basté Rotllan, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Nepote</last_name>
    <phone>0034 934344412</phone>
    <email>investigacion@mfar.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Luisa Duran Sanchez, Clinical Research Coordinator (TTCC)</last_name>
    <phone>0034 690756714</phone>
    <email>mduran@ttccgrupo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Durán i Reinals</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034 934344412</phone>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundació Althaia</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034 934344412</phone>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consorci Corporació Sanitària Parc Taulí de Sabadell</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034 934344412</phone>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034 934344412</phone>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034 934344412</phone>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia Girona - ICO Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034 934344412</phone>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034 934344412</phone>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034 934344412</phone>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034 934344412</phone>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034 934344412</phone>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034 934344412</phone>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MFAR Sponsor designated contact point</last_name>
      <phone>0034 934344412</phone>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced and/or metastatic disease</keyword>
  <keyword>iodine refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

